Lucentis 0.5 mg/0.05 ml (Intravitreal Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranibizumab |
| Company | Novartis bangladesh ltd |
Indications
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (Non Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR)) in patients with Diabetic Macular Edema (DME)
- Myopic Choroidal Neovascularization (mCNV)
Pharmacology
Ranibizumab is a recombinant humanised IgG1 kappa monoclonal antibody fragment which binds to active forms of human vascular endothelial growth factor A (VEGF-A) and inhibits their biologic activity. Binding of ranibizumab to VEGF-A inhibits VEGF from binding to its receptors, thereby suppressing neovascularisation (angiogenesis), endothelial cell proliferation and vascular permeability.
Dosage & Administration
- Intravitreal administration for different conditions with specific dosages and treatment intervals.
Interaction
May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively with verteporfin photodynamic therapy (PDT).
Contraindications
- Active or suspected ocular or periocular infection
- Active severe intraocular inflammation
- Signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion
Side Effects
- Ocular pain
- Hyperaemia
- Irritation and pruritus
- Increased intraocular pressure
- Vitritis
- Vitreous detachment
- Retinal haemorrhage
- Visual disturbance
- Vitreous floaters
- Conjunctival haemorrhage
- Foreign body sensation in eyes
- Increased lacrimation
- Blepharitis
- Dry eye
- Headache
- Nasopharyngitis
- Arthralgia
- Thromboembolic events
- Endophthalmitis
- Blindness
- Retinal detachment
- Retinal tear
- Iatrogenic traumatic cataract
Pregnancy & Lactation
Pregnancy Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Precautions & Warnings
- Patient with risk factors for retinal pigment epithelial tears
- History of stroke or transient ischaemic attack
- Uncontrolled HTN
- Previous intravitreal inj
- Active systemic infections
- Proliferative diabetic retinopathy
- Diabetic macular oedema due to type 1 DM
- Discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular hole develops
- Diabetic patients w/ glycosylated Hb over 12%
Overdose Effects
- Symptoms: Increased intraocular pressure, transient blindness, reduced visual acuity, corneal oedema, corneal pain, and eye pain.
- Management: Intraocular pressure should be monitored and treated by the attending physician, if necessary.
Therapeutic Class
Drugs for Age-Related Macular Degeneration (AMD)
Storage Conditions
Store between 2-8°C. Protect from light.